Last reviewed · How we verify
TR-701 free acid phosphate
At a glance
| Generic name | TR-701 free acid phosphate |
|---|---|
| Sponsor | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (PHASE3)
- TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections (PHASE3)
- Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) (PHASE1)
- Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: